FITC Anti-Mouse/Rat CD29 Antibody

Product Details


CloneHMβ1-1
ApplicationFlow Cytometry
ReactivityMouse
FormatFITC
Target NameCD29, Integrin β1 chain, VLA-β chain, gpIIa, ITGB1
IsotypeArmenian Hamster IgG
Antibody TypeMonoclonal
Regulatory StatusRUO
FormulationPhosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and 0.2% (w/v) BSA
Protein ConcentrationSupplied at a lot-specific concentration.
Storage&HandlingThe antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Recommended UsageFor flow cytometric staining, it is recommended to use 5 uL of this reagent per 0.5-1.0 million cells in a 100 µL volume. Optimal reagent performance should be determined by titration for each specific application. FITC has an excitation max at 493 nm and an emission max at 525 nm.
Excitation LaserBlue Laser (488 nm) Green/Yellow laser (532/561nm)
See All FormatsClone HMβ1-1

Background Information


CD29, also known as integrin β1 (ITGB1), is a ubiquitously expressed transmembrane adhesion receptor that forms the β1 subunit of at least 12 different integrin heterodimers through pairing with distinct α integrin subunits (including α1–α11 and αV). These heterodimers mediate cell adhesion to the extracellular matrix (ECM) and neighboring cells, regulating processes such as cell migration, proliferation, survival, differentiation, and tissue organization. CD29 is expressed on nearly all cell types, including leukocytes, epithelial cells, endothelial cells, fibroblasts, and stem cells, where it serves as a key mediator of tissue homeostasis and immune cell trafficking.

Structurally, CD29 is a type I transmembrane glycoprotein composed of a large extracellular domain, a single transmembrane helix, and a short cytoplasmic tail. The extracellular domain undergoes conformational changes that switch the receptor between inactive and high-affinity states, while the cytoplasmic tail interacts with adaptor proteins such as talin and kindlin to connect integrins to the actin cytoskeleton. CD29-containing integrins bind numerous extracellular ligands, including fibronectin, collagen, laminin, vitronectin, thrombospondin, and vascular cell adhesion molecule-1 (VCAM-1), depending on the associated α subunit. These interactions enable bidirectional signaling, whereby extracellular ligand binding influences intracellular signaling ("outside-in" signaling) and intracellular signals regulate ligand affinity ("inside-out" signaling).

Dysregulation of CD29 contributes to numerous diseases. Increased β1 integrin signaling promotes tumor growth, invasion, metastasis, resistance to chemotherapy, and survival of cancer stem cells. CD29 also plays important roles in fibrosis, chronic inflammation, autoimmune diseases, cardiovascular disease, and wound healing. In immune cells, β1 integrins regulate leukocyte adhesion and migration into inflamed tissues, making them important mediators of inflammatory responses.

Because of its central role in cell adhesion and signaling, CD29 has emerged as an important therapeutic target. Inhibitors of β1 integrins, blocking antibodies, peptides, and small molecules are being investigated to suppress tumor progression, reduce fibrosis, and limit inflammatory cell recruitment. Conversely, CD29 is widely used as a marker for mesenchymal stem cells and activated lymphocytes, and modulation of β1 integrin signaling is being explored to improve stem cell engraftment, tissue regeneration, and adoptive cell therapies such as CAR-T cell treatment.

Isotype Control


iF647 Armenian Hamster IgG Isotype Control Antibody

Data Sheets


FITC Anti-Mouse/Rat CD29 Antibody TDS

Related Protocols


Flow Cytometry Protocol


Have a product or application question? Consult our FAQs or contact us.